Profound Medical Corp. (TSX: PRN)

Market Cap	263.88M
Revenue (ttm)	12.14M
Net Income (ttm)	-42.41M
Shares Out	24.66M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,003
Open	10.75
Previous Close	10.86
Day's Range	10.40 - 10.85
52-Week Range	9.55 - 15.75
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 131
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: PRN

Financial Performance

In 2023, Profound Medical's revenue was $7.20 million, an increase of 7.75% compared to the previous year's $6.68 million. Losses were -$28.57 million, -0.35% less than in 2022.

Financial numbers in USD